Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis
Authors:
- Aimee AlexoffAAAimee Alexoff
- Eli D. EhrenpreisEEEli D. Ehrenpreis
- 1 October 2015
- journal article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 49 (9) , 794-795
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitisBMC Immunology, 2015
- Mesenteric panniculitis: an updateExpert Review of Gastroenterology & Hepatology, 2014
- Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s DiseaseJournal of Clinical Gastroenterology, 2013
- The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trialMultiple Sclerosis Journal, 2010
- Low-Dose Naltrexone Therapy Improves Active Crohn's DiseaseAmerican Journal of Gastroenterology, 2007
- A pilot study of thalidomide for patients with symptomatic mesenteric panniculitisAlimentary Pharmacology & Therapeutics, 2002
- Naltrexone modulates growth in infant ratsLife Sciences, 1983